In summary, these results collectively demonstrate that therapeutic targeting of Rac is a promising therapeutic strategy for breast cancer, particularly in cancers harboring activating mutations in PIK3CA or amplification of HER2. The gene discussed is ERBB2; the disease is breast carcinoma.